AI-Assisted Cancer Diagnosis Company Nucleai Raises $5M

Nucleai, a company developing an artificial intelligence system for computerized analysis of biopsies, has raised $5 million in a funding round led by top Israeli VC Grove Ventures and Vertex Ventures. The AI system aims to assist in cancer diagnosis by analyzing biopsies, addressing the challenge of human error and the shortage of pathology manpower. Nucleai was founded by a team with expertise in computerized vision from their service in the IDF Intelligence Corps. The company is focusing on prostate, breast, and gastrointestinal cancers and aims to improve accuracy and efficiency in pathology while potentially leading to breakthroughs in personalized medicine.

>> Click here to read the full article originally published in Globes: AI-assisted cancer diagnosis co Nucleai raises $5m